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Abstract
Aim:  Once considered a problem of developed countries, obesity and obesity-related
complications (such as metabolic syndrome) are rapidly spreading around the globe. The purpose
of the present study was to investigate the use of a Cissus quadrangularis formulation in the
management of metabolic syndrome, particularly weight loss and central obesity.
Methods: The study was a randomized, double-blind, placebo-controlled design involving 123
overweight and obese persons (47.2% male; 52.8% female; ages 19–50). The 92 obese (BMI >30)
participants were randomized into three groups; placebo, formulation/no diet, and formulation/diet
(2100–2200 calories/day). The 31 overweight participants (BMI = 25–29) formed a fourth (no diet)
treatment group. All participants received two daily doses of the formulation or placebo and
remained on a normal or calorie-controlled diet for 8 weeks.
Results: At the end of the trial period, statistically significant net reductions in weight and central
obesity, as well as in fasting blood glucose, total cholesterol, LDL-cholesterol, triglycerides, and C-
reactive protein were observed in participants who received the formulation, regardless of diet.
Conclusion: Cissus quadrangularis formulation appears to be useful in the management of weight
loss and metabolic syndrome.
Background
Although still defined in diverse terms, metabolic syn-
drome is a common disorder arising as a result of the
increased prevalence of obesity throughout the world [1].
Metabolic syndrome, also known as insulin resistance
syndrome and Syndrome X, has 3 main potential etiologic
categories: obesity and disorders of adipose tissue; insulin
resistance; and a constellation of independent factors
(e.g., molecules of hepatic, vascular, and immunologic
origin) that mediate specific components of the metabolic
syndrome [2].
In the United States, over 60% of the adult population is
now overweight or obese [3] and 47 million people have
metabolic syndrome, which will soon overtake cigarette
smoking as the number one risk factor for heart disease
[4,5]. Globally, the disorder has become a major public
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health challenge. (In Cameroon, approximately 25% of
the population is now considered obese.)
Obesity has been shown to contribute to high serum cho-
lesterol, low HDL cholesterol and hyperglycemia, all of
which increase the chances of cardiovascular disease
(CVD) [6-8]. Correlations between central obesity and
high blood pressure, high blood cholesterol, low levels of
high density lipoprotein-cholesterol, and high fasting
blood glucose levels have been shown for both sexes in
various racial and ethnic groups [6-10].
Since it has been determined that abdominal fat poses a
greater health risk than fat stored in the lower half of the
body [11], waist circumference has become a major factor
in body-fat assessment [12,13]. A large waist circumfer-
ence (>88 cm in women and 102 cm in men) is associated
with an increased risk for type 2 diabetes, dyslipidemia,
hypertension and CVD in patients with a body mass index
(BMI) 25–34 [8]. Moreover, for obese patients with meta-
bolic complications, changes in waist circumference are
useful predictors of CVD risk factors [13,14]. Thus, in
addition to weight (kg), fat (%) and BMI, changes in waist
measurement (cm) was one of the primary endpoints in
this study.
Because of its links with obesity, it is difficult to identify a
unique role for insulin resistance in patients with meta-
bolic syndrome. Although insulin resistance generally
rises with increasing body fat content, one finds a broad
range of insulin sensitivities at all levels [6]. Although
most people with BMI ≥ 30 have postprandial hyperin-
sulinemia and relatively low insulin sensitivity, there is
variation in insulin sensitivity even within the obese pop-
ulation [6,7]. Overweight persons (BMI 25–29) also
exhibit a spectrum of insulin sensitivities, which seems to
suggest an inherited component to insulin resistance.
The increased chance of CVD and type 2 diabetes require
therapeutic consideration for the vast numbers of over-
weight/obese persons now at high risk for these diseases
[1]. The current International Diabetes Foundation rec-
ommendations for preventing or delaying the develop-
ment of diabetes include both primary and secondary
interventions. The former emphasizes lifestyle changes
such as calorie restriction and increased physical activity,
and the latter (for people at high risk for CVD) uses phar-
macological agents [15] that specifically target individual
components of metabolic syndrome [15-20]. When used
by obese patients in combination with dietary regimes,
these agents can produce some weight loss and some
reversal of accompanying complications. The role of phar-
macotherapy, however, has been compromised by safety
issues leading to the withdrawal of some medications
from the market [21,22]. The combination of safety con-
cerns and high costs have forced many populations to
continue to rely on traditional healing methods using the
indigenous pharmacopoeia.
Cissus quadrangularis, for example, is used by common
folk in India to hasten the fracture healing process [23-
28]. In Cameroon, the whole plant is used in oral re-
hydration, while in Africa and Asia the leaf, stem, and root
extracts are utilized in the management of various ail-
ments [29-33]. Phytochemical analyses of Cissus quadran-
gularis reveal a high content of ascorbic acid, carotene,
phytosterol substances and calcium [34,35], and there
have also been reports of the presence of β-sitosterol, δ-
amyrin and δ-amyrone [36]. All these components have
potentially different metabolic and physiologic effects
[37,38]. Although researchers have investigated several
uses of Cissus quadrangularis, its potential application
against metabolic syndrome has not yet been reported.
Several other dietary supplements (green tea, soy, chro-
mium, selenium, B-vitamins) have only marginal effects
in treating obesity but they address other metabolic syn-
drome symptoms and thus were included in the formula-
tion. Green tea (Camellia sinensis) extracts contain high
concentrations of epigallocatchin gallate and may work
with other chemicals to increase levels of fat oxidation
and thermogenesis [39,40]. Numerous studies on soy
(Glycine max) protein show it is associated with a reduc-
tion in serum cholesterol and triglyceride levels and sug-
gest it may protect against the development of coronary
heart disease [41]. Chromium helps insulin metabolize
fat, turn protein into muscle, and convert sugar into
energy [42]; thus, chromium supplementation can favora-
bly influence glucose/insulin metabolism, reduce levels of
harmful LDL cholesterol, and increase HDL cholesterol
[43]. Both humans and animals require selenium for the
optimal functioning of the selenoproteins, which reduce the
risk of CVD by decreasing lipid peroxidation and influ-
encing the metabolism of the cell-signaling prostagland-
ins [44]. Lastly, B-vitamins (B-6, B-12 and folic acid)
regulate energy metabolism [45], which plays a critical
role in obesity management; they also maintain lower
homocysteine levels [46], which are closely associated
with cardiovascular health benefits.
The purpose of the present study was to examine the effi-
cacy of a Cissus quadrangularis formulation (Cylaris™) con-
taining the above agents in the management of obesity
and metabolic syndrome.
Methods
The study was a prospective, randomized, double blind,
placebo-controlled design conducted by the Laboratory
for Nutrition and Nutritional Biochemistry at the Univer-
sity of Yaoundé I, Cameroon, Africa. The CameroonLipids in Health and Disease 2006, 5:24 http://www.lipidworld.com/content/5/1/24
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National Ethics Committee approved the protocol. Appli-
cants were advised of the study's purpose, nature, and
potential risks, and all gave their written informed con-
sent before participation. The study was conducted in
accordance with the Helsinki Declaration (1983 version).
Participants
Eligibility criteria included meeting the minimal stand-
ards for overweight (i.e., a BMI >25 and a waist circumfer-
ence >85.5 cm.) and a willingness to participate in an 8-
week trial. Exclusion criteria (confirmed via an initial
interview and physical examination) included pregnancy/
lactatation, use of any form of weight-reducing medica-
tion, participation in intense exercise programs, medical
conditions known to affect serum lipids, and a history of
drug or alcohol abuse. For the 123 eligible participants,
BMIs ranged from 25.5 to 45.6; waist circumferences from
85.5 cm to 125 cm; and weight from 62.6 kg to 142 kg.
(See Table 1 for other baseline characteristics.) Ninety-two
persons qualified as obese (BMI >30), and 31 as over-
weight (BMI = 25–29). The age range was 19 to 50; males
= 47.2%; females = 52.8%.
Intervention
The 92 obese persons were randomized to a placebo or
one of two treatment groups; the 31 overweight persons
formed a fourth group. One obese treatment group was
prescribed a calorie-controlled (2100–2200 calories/day)
diet; none of the groups was prescribed an exercise regi-
men. Apart from the expected lower anthropomorphic
and serological characteristics of the overweight group,
none of the baseline differences between the groups was
clinically significant.
The overweight group was used for general comparison
with the obese groups, thus the results were expressed in
percentages rather than absolute values. The formulation/
diet group was used to determine if a short-term, calorie-
controlled diet would significantly increase anthropomor-
phic and serological outcomes compared to the formula-
tion/non-diet group.
Materials
The  Cissus quadrangularis formula, Cylaris™, contains a
Cissus quadrangularis extract (supplied by Gateway Health
Alliances, Inc, Fairfield, California, USA), standardized to
contain a minimum of 2.5% phytosterols and a mini-
Table 1: Baseline (week 0) characteristics of study participants
BMI Greater than 30 (Obese) 25 – 29 (Overweight)
Treatment Placebo (n = 
30)
Formulation/no diet (n = 
31)
Formulation/Diet (n = 
31)
Formulation/no diet (n = 
31)
Demographic Characteristics (no.)
Sex
Male 14 15 14 15
Female 16 16 17 16
Age (years)* 39.9 (9.6) 41.0 (9.4) 40.9 (9.8) 39.7 (9.9)
Race or ethnic group
West African 30 31 31 31
Family History of Diabetes 2 1 0 2
History of Gestational Diabetes 2 2 3 2
Anthropomorphic 
Characteristics*1
Weight (kg) 95.6 (14.3) 95.8 (8.0) 95.3 (9.1) 76.3 (7.9)
Fat (%) 41.8 (5.2) 46.5 (5.8) 48.1 (3.0) 35.8 (5.2)
Body Mass Index (kg/m2) 38.4 (1.6) 37.7 (1.5) 37.5 (1.0) 27.3 (0.7)
Waist Circumference (cm) 103.4 (8.1) 98.6 (4.6) 97.8 (5.7) 86.9 (3.2)
Serological Characteristics*2
Total Cholesterol (mg/dl) 160.8 (18.0) 159.1 (30.7) 171.0 (24.4) 152.6 (26.9)
LDL Cholesterol (mg/dl) 103.5 (14.9) 99.8 (11.7) 116.6 (15.4) 101.6 (17.0)
HDL Cholesterol (mg/dl) 32.7 (7.5) 36.6 (8.0) 38.6 (7.1) 44.4 (9.8)
Triglycerides (mg/dl) 142.5 (31.8) 156.0 (25.3) 144.9 (30.0) 117.4 (25.3)
C-Reactive Protein (mg/dl) 8.0 (1.1) 8.0 (1.0) 8.1 (0.7) 7.8 (0.8)
Fasting Blood Glucose (mg/dl) 101.6 (11.9) 101.2 (15.9) 102.4 (9.8) 93.3 (12.4)
* These data are shown as means with standard deviations in parentheses
1 Primary outcome measures
2 Secondary outcome measuresLipids in Health and Disease 2006, 5:24 http://www.lipidworld.com/content/5/1/24
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mum of 15% soluble plant fiber. The formula also con-
sists of a soy albumin extract (supplied by Gateway Health
Alliances, Inc, Fairfield, California, USA); a green tea
extract standardized to 22% EGCG and 40% caffeine;
niacin bound chromium (ChromeMate™ supplied by
InterHealth Nutraceuticals, Inc, Benicia, California, USA);
selenium standardized to 0.5% l-Selenomethionine; vita-
min B6 (as pyridoxine hydrochloride); vitamin B12 (as
cyanocobalamin); and folic acid (supplied by Protein
Research, Inc, Livermore, California, USA). All active and
placebo capsules were manufactured and bottled by Pro-
tein Research, Inc.
Participants received two daily doses (514 mg each) of the
Cissus formulation or placebo for 8 weeks. Each capsule
was taken with 8–12 oz of water immediately prior to
meals (preferably breakfast and dinner). In keeping with
the experimental design, the capsules were identical in
shape, color and appearance, and neither the participants
nor researchers knew which capsule was administered.
Side effects were noted on each visit.
Body weight and percentage of body fat were determined
in the 12-hour- fasted participants with a Tanita™ BC-418
Segmental Body Composition Analyzer/Scale that uses
bio-electrical impedance analysis for body composition
analysis. Height was measured with a Harpended™ stadi-
ometer, which measures the length of curved line staffage
to the nearest 0.5 cm.
Blood (5 ml) samples were collected after an overnight
fast at the start and end of the 8 week trial period. The
blood was collected into vacutainer tubes, and the serum
was separated (via centrifugation) and stored (200 μl aliq-
uots) at -20°C until needed for analyses. The concentra-
tions of total cholesterol, triacylglycerol, HDL-cholesterol,
LDL-cholesterol, and glucose were measured using com-
mercial diagnostic kits (cholesterol Infinity, triglyceride
Infinity, EZ HDL™ cholesterol, EZ LDL™ cholesterol, Glu-
cose Trinder) from SIGMA Diagnostics. C-reactive protein
was measured using an ELISA method (BioCheck™ hsC-
Reactive Protein ELISA kit, Foster City, CA USA).
Statistical analyses
The data for each parameter was summarized via n, mean,
and standard deviation for Week 0 and Week 8 and the
percent difference (Week 8 – Week 0/week 0). The percent
change from baseline was tested for differences using
analysis of variance. Contrasts were used for testing pair-
wise differences.
Results
Anthropomorphic characteristics
Waist circumference is an extremely important determi-
nant in the diagnosis of obesity and metabolic syndrome.
As shown in Table 2, the significant reduction in this var-
iable across all treatment groups was paralleled by signif-
icant reductions in weight and BMI for the two obese
treatment groups.
To translate the percentage loss over 8 weeks into actual
measurements, the mean change in weight (kg) for the 3
obese (BMI >30) groups was 95.6 to 93.3 (placebo); 95.8
to 89.2 (formulation/no diet); and 95.3 to 87.2 (formula-
tion/diet). The mean change for the overweight (BMI 25 –
29) group was 76.3 to 72.6 kg (formulation/no diet).
Thus, over a period of 8 weeks, the placebo group lost 2.3
kg; the overweight group lost 3.7 kg and the two obese
groups lost 6.6 kg and 8.1 kg, respectively.
Serological characteristics
As shown in Table 3, there was a significant improvement
in virtually every measurement for the three treatment
groups vs. placebo. Eight-week use of the Cissus formula-
tion significantly reduced plasma total cholesterol and
Table 2: Effectiveness of Cissus quadrangularis formulation on anthropomorphic characteristics: Percent difference in means from 
Week 0 to Week 8
BMI Greater than 30 (Obese) 25 – 29 (Overweight)
Treatment Placebo (n = 30) Formulation/no diet (n = 
31)
Formulation/Diet (n = 31) Formulation/no diet (n = 
31)
Anthropomorphic 
Characteristics*
Weight (%) -2.4 (4.9) -6.9 (6.8)c -8.5 (11.3)a -4.8 (6.0)
Fat (%) -1.9 (9.6) -6.0 (8.4) -8.0 (7.6)b -4.7 (9.4)
Body Mass Index (%) -1.0 (4.2) -8.3 (3.8)a -9.9 (2.7)a -3.9 (3.0)a
Waist Circumference (%) -2.0 (7.2) -6.6 (4.9)a -8.4 (6.7)a -11.2 (4.7)a
* These data are shown as means with standard deviations in parentheses
a P = <0.001 versus placebo
b P = <0.01 versus placebo
c P = <0.05 versus placeboLipids in Health and Disease 2006, 5:24 http://www.lipidworld.com/content/5/1/24
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LDL cholesterol in the three treatment groups and
increased HDL cholesterol in the two obese groups by
50.5 % and 43.0% The increase in the concentration of
circulating HDL-cholesterol in the three treatment groups
shows a large reduction in the ratio of total cholesterol to
HDL-cholesterol ratios as well as LDL-cholesterol to HDL-
cholesterol ratios. All three treatment groups also demon-
strated a significant decrease in triglycerides, C- reactive
protein, and fasting blood glucose levels.
To translate the percentage loss over 8 weeks into actual
measurements, the mean change in Total cholesterol (mg/
dl) for the 3 obese (BMI >30) groups was 160.8 to 155.8
(placebo); 159.1 to 116.1 (formulation/no diet); and
171.0 to 126.5 (formulation/diet. The mean change for
the overweight (BMI 25 – 29) group was 152.6 to 123.9.
Thus, over a period of 8 weeks, Total cholesterol declined
5.0 mg/dl for the placebo group; 28.7 mg/dl for the over-
weight group; and 43.0 mg/dl and 44.5 mg/dl for the two
obese groups.
Adverse events
Adverse events with an incidence >5 included headache
(12), gas (11), dry mouth (7), diarrhea (7), and insomnia
(6). Since the incidence of all reported side effects was
always higher in the placebo group than in any of the
treatment groups, it is probably safe to conclude that the
Cissus formulation had few, if any, negative side effects.
Discussion
Our results support the hypothesis that the use of a Cissus
quadrangularis  formulation has efficacy in the manage-
ment of weight loss and metabolic syndrome, particularly
for central obesity. The use of the formulation (which also
contains green tea, soy, chromium, selenium, and B-vita-
mins) over an 8-week period brought about a significant
reduction in many of the anthropomorphic measures:
weight, % body fat, BMI and, especially, waist circumfer-
ence of obese and overweight patients, regardless of calo-
rie-controlled diet (see Table 2).
Waist circumference is a particularly important factor in
weight and body-fat assessment since fat distribution,
rather than total body fat, is currently the key indicator of
weight-related health problems. The dramatic reduction
in waist circumference that accompanied the 8-week use
of the Cissus quadrangularis formulation for both the diet
and no diet groups is particularly important because waist
circumference is a major criterion in the diagnosis of obes-
ity and metabolic syndrome [2] and is generally consid-
ered a surrogate measure for abdominal visceral fat
[12,13]. Moreover, not only does the risk of type 2 diabe-
tes increase with the degree and duration of obesity it, too,
is associated with central obesity [6,7].
The reduction in the primary anthropomorphic measure-
ments can be attributed to the synergistic effects of Cyla-
ris™,  Glycine max extract,  Camellia sinensis extract and
ChromeMate™ ingredients in the formula, all of which
have previously been shown to affect weight loss activity
[32,35,39,41,42].
Cissus quadrangularis phytosterols and fiber extracts have
been shown to have anti-lipase, and anorexiant properties
that reduce the absorption of dietary fats and enhance
satiation by increasing serum serotonin levels [47]. In
1999, Swiss researchers found that men who were given a
combination of caffeine and green tea catechin extract
burned more calories than those given only caffeine or a
placebo. It was postulated that the catechins and caffeine
combination sustained the effect of norepinephrine on
Table 3: Effectiveness of Cissus quadrangularis formulation on serological characteristics: Percent difference in means from Week 0 to 
Week 8
BMI Greater than 30 (Obese) 25 – 29 (Overweight)
Treatment Placebo (n = 30) Formulation/no diet (n = 
31)
Formulation/Diet (n = 31) Formulation/no diet (n = 
31)
Serological 
Characteristics*
Total Cholesterol (%) -3.1 (28.7) -27.0 (14.6)a -26.0 (13.3)a -18.8 (17.0)b
LDL Cholesterol (%) -10.4 (13.4) -18.4 (9.8)c -32.4 (15.5)a -26.4 (12.8)a
HDL Cholesterol (%) 17.4 (38.8) 50.5 (50.7)b 43.0 (39.5)c 19.6 (37.0)
Triglycerides (%) -4.5 (25.4) -36.8 (17.8)a -28.0 (12.2)a -15.0 (15.3)c
C-Reactive Protein (%) 0.8 (13.2) -20.8 (11.2)a -20.8 (10.0)a -16.3 (13.2)a
Fasting Blood Glucose (%) -4.6 (14.8) -13.4 (13.6)b -16.1 (13.4)a -11.4 (11.8)c
* These data are shown as means with standard deviations in parentheses
a P = <0.001 versus placebo
b P = <0.01 versus placebo
c P = <0.05 versus placeboLipids in Health and Disease 2006, 5:24 http://www.lipidworld.com/content/5/1/24
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thermogenesis longer than caffeine alone [39]. Numerous
studies on chromium supplementation have also demon-
strated weight loss in overweight and obese people
[48,49]. Grant et al. (1997) reported that chromium with
a moderate diet and exercise regimen influences weight
loss and body composition [50].
The modification of certain serological characteristics
(blood parameters) (see Table 3) by Cissus formulation
may or may not be dependent on weight loss. Only the
reduction of LDL-cholesterol followed a similar pattern to
weight loss over the 8-week trial period. The circulating
concentration of total cholesterol and triglycerides,
though reduced by the formulation, could be independ-
ent of weight loss since all treatment groups (diet/no diet)
showed significant cholesterol reduction. The increase in
the concentration of circulating HDL-cholesterol in the
treatment groups shows a reduction in the ratio of total
cholesterol to HDL-cholesterol as well as LDL-cholesterol
to HDL-cholesterol. This reduced ratio also implies a
reduction in the risk of atherosclerosis and coronary heart
disease [51].
Although the exact mechanisms for the formulation's cho-
lesterol-lowering ability needs further study, the various
ingredients might interact in a manner similar to statins,
fibrates, probucol, nicotinic acid or cholesterol absorp-
tion inhibitors. Green tea catechins have a number of anti-
oxidant activities related to cholesterol regulation. For
example, the inhibition of the oxidation of low-density
lipoproteins and the antithrombotic activity both aid in
lowering total cholesterol/LDL-cholesterol and increasing
HDL-cholesterol levels [52,53]. Also, the phytochemical
constituents (phytosterols, β-sitosterol, δ-amyrin and δ-
amyrone), in Cissus quadrangularis may have activity simi-
lar to other plant sterols. The molecular structure of phy-
tosterols, for example, is practically identical to that of
cholesterol.
Recent studies show that metabolic syndrome causes an
inflammatory process in the blood vessels that leads to
arteriosclerosis. This inflammatory process can be gauged
by blood levels of C-reactive protein [54] and, as our
results showed, Cissus formulation significantly reduced
the circulating concentrations of CRP thereby inhibiting
the inflammatory process and possibly reducing individ-
ual components of metabolic syndrome [54]. In meta-
bolic syndrome, the body becomes resistant to insulin,
and high levels of glucose remain trapped in the blood. In
response, the pancreas produces more insulin. The extra
insulin temporarily allows glucose to enter the cells and
also increases cholesterol and triglyceride levels.
In sum, Cissus formulation administered twice daily to
obese and overweight persons with symptoms of meta-
bolic syndrome results in both weight reduction and an
improvement in the symptoms associated with metabolic
syndrome. It has also shown efficacy in the control and
lowering of triglyceride concentrations, total cholesterol,
LDL-cholesterol, and fasting blood glucose. The formula-
tion may also have applications in other metabolic dis-
eases, such as diabetes mellitus.
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